Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes
Robbins LLP Urges ARDX Stockholders Who Lost Money Investing in Ardelyx, Inc. to Contact the Firm for Information About Leading the Class ActionShareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Ardelyx, Inc. (
NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). Ardelyx, Inc. develops and commercializes medicines, including IBSRELA for the treatment of irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis.
ARDX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Ardelyx, Inc. Securities Lawsuit - Contact Levi & KorsinskyNEW YORK CITY, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP notifies institutional investors in Ardelyx, Inc. (
NASDAQ:ARDX), including pension funds, asset managers, and other fiduciaries, that a securities class action has been filed on behalf of shareholders who purchased ARDX securities between January 13, 2025 and August 6, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (
NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Kaplan Fox Encourages Ardelyx, Inc. (NASDAQ: ARDX) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 16, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Kaplan Fox Encourages Investors of Ardelyx, Inc. (NASDAQ: ARDX) to Contact the Firm Before Lead Plaintiff Deadline on November 16, 2026Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer AwardsRecognition includes Life Sciences Manufacturer CEO of the Year, Podcast Initiative, and Marketing Team of the Year
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDXNEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx” or the “Company”) (
NASDAQ: ARDX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (
NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Kaplan Fox Encourages Investors of Ardelyx, Inc. (NASDAQ: ARDX) to Contact the Firm to Learn About Their Legal RightsSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (
NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS LawLOS ANGELES, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (
NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their RightsRosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ardelyx, Inc. (
NASDAQ: ARDX) between January 13, 2025 and August 6, 2026, inclusive (the “Class Period”). Ardelyx develops and commercializes medicines.
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – ARDXThe DJS Law Group reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (
NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ardelyx, Inc. (“Ardelyx” or “the Company”) (
NASDAQ: ARDX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
ARDX SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ardelyx, Inc. (“Ardelyx” or the “Company”) (
NASDAQ: ARDX) and reminds investors of the November 16, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
ARDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ardelyx To Contact Him Directly To Discuss Their Options
Investor Alert: Robbins LLP Informs Investors of the Ardelyx, Inc. Class Action LawsuitShareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Ardelyx, Inc. (
NASDAQ: ARDX) common stock between January 13, 2025 and August 6, 2026, inclusive (the "Class Period"). Ardelyx, Inc. develops and commercializes medicines, including ISBRELA for the treatment of irritable bowel syndrome with constipation and XPHOZAH for reducing serum phosphorus in adults with chronic kidney disease on dialysis.
ARDX INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Ardelyx, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the FirmATLANTA, Sept. 18, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Ardelyx, Inc. (“Ardelyx”) (
NASDAQ: ARDX). The lawsuit alleges that Ardelyx made materially false and misleading statements about its two core drugs, IBSRELA and XPHOZAH.
